Zimmer Biomet Holdings (ZBH) 129.40 $ZBH Zimmer
Post# of 273257
Posted On: 09/05/2016 7:11:54 AM
Zimmer Biomet Holdings (ZBH) 129.40 $ZBH
Zimmer Biomet's LDR Buyout On Track, Dental Still a Pain
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:45AM CDT
On Sep 2, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Zimmer Biomet Holdings to Present at INVESTIndiana Equity Conference
PR Newswire - Thu Sep 01, 3:30PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced that it will be participating in the INVESTIndiana Equity Conference at the Indianapolis Marriott Downtown on Thursday, September 15, 2016 at 1:10 p.m. Eastern Time.
ZBH: 129.40 (+1.05)
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2016
PR Newswire - Tue Aug 23, 6:30AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2016.
ZBH: 129.40 (+1.05)
Zimmer Biomet Holdings to Present at Morgan Stanley 2016 Global Healthcare Conference
PR Newswire - Thu Aug 18, 4:00PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced that it will be participating in the Morgan Stanley 2016 Global Healthcare Conference at the Grand Hyatt hotel in New York. Zimmer Biomet will present on Monday, September 12, 2016 at 9:20 a.m. Eastern Time.
ZMH: 113.56 (+0.29), ZBH: 129.40 (+1.05), MS: 31.89 (-0.02)
Technical Roundup on Medical Appliances & Equipment Stocks -- Zimmer Biomet, Stryker, ABIOMED, and Spectranetics
PR Newswire - Thu Aug 18, 7:31AM CDT
Stock-Callers.com is currently focused on the Medical Appliances and Equipment segment, which includes companies that manufacture medical supplies such as surgical and medical instruments, dental equipment, and surgical appliances. According to IBISWorld, global revenue of this industry is about $350 billion. Let us take a look at today's lineup: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Stryker Corp. (NYSE: SYK), ABIOMED Inc. (NASDAQ: ABMD), and The Spectranetics Corp. (NASDAQ: SPNC). Sign up today and download for free the research reports for the stocks covered today at:
SPNC: 24.86 (+0.17), ABMD: 117.43 (-0.20), ZBH: 129.40 (+1.05), SYK: 115.60 (+0.37)
Zimmer Biomet Acquires CD Diagnostics, Targets PJI Market
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:27AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) announced the buyout of CD Diagnostics, an immunoassays and biomarker testing developer.
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Zimmer Biomet to Present at 11th Annual Wells Fargo Securities Healthcare Conference
PR Newswire - Tue Aug 16, 4:00PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that it will be participating in the 11th Annual Wells Fargo Securities Healthcare Conference at the Westin Boston Waterfront hotel in Boston, Massachusetts. Zimmer Biomet will present on Wednesday, September 7, 2016 at 9:55 a.m. Eastern Time.
ZBH: 129.40 (+1.05), WFC: 50.55 (+0.12)
Zimmer Biomet Strengthens Musculoskeletal Diagnostic Offering with Acquisition of CD Diagnostics
PR Newswire - Mon Aug 15, 7:03AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the acquisition of CD Diagnostics, a fully-integrated, Delaware-based diagnostics company focused on developing immunoassays and biomarker testing to inform treatment decisions that improve patient outcomes. The financial terms of the transaction were not disclosed.
ZBH: 129.40 (+1.05)
Zimmer Biomet Holdings Announces Pricing of Secondary Offering of Common Stock
PR Newswire - Wed Aug 10, 7:19AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced the pricing of the previously announced underwritten secondary offering of 7,440,675 shares of its common stock by certain of its stockholders, consisting of affiliates of KKR and TPG. The shares are being sold to the public at an initial price of $129.75 per share. The selling stockholders will receive all of the proceeds of the offering. Neither Zimmer Biomet nor any of its directors, officers or other stockholders is selling any shares of common stock in the offering. The closing of the offering is expected to occur on August 12, 2016, subject to the satisfaction of customary closing conditions.
ZBH: 129.40 (+1.05)
Zimmer Biomet Holdings Announces Launch of Secondary Offering of Common Stock
PR Newswire - Tue Aug 09, 3:08PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that certain of its stockholders, consisting of affiliates of KKR and TPG, intend to offer for sale in an underwritten secondary offering 7,440,675 shares of the common stock of Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"
. The selling stockholders will receive all of the proceeds of the offering. Neither Zimmer Biomet nor any of its directors, officers or other stockholders is offering shares of common stock in the offering.
ZBH: 129.40 (+1.05)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Raises FY16 Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 1:57PM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported second-quarter 2016 adjusted earnings per share (EPS) of $2.02, up 27.8% year over year.
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), BAX: 46.28 (+0.10), VASC: 48.99 (+0.53)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Revenue Estimates
Aparajita Dutta - Zacks Investment Research - Thu Jul 28, 7:56AM CDT
Zimmer Biomet's (ZBH) adjusted earnings per share of $2.02 beat this estimate by 3.1%.
ZBH: 129.40 (+1.05)
Zimmer Biomet Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Jul 28, 6:30AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2016. The Company reported second quarter net sales of $1.93 billion, an increase of 65.6% and an increase of 4.5% on an adjusted pro forma, constant currency basis, compared to the second quarter of 2015. Diluted net loss per share for the quarter was $(0.16), compared to a net loss per share of $(1.00) for the prior year period, and adjusted diluted earnings per share for the quarter were $2.02, an increase of 27.8% adjusted over the prior year period.
ZBH: 129.40 (+1.05)
CVS Health (CVS) Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:43PM CDT
CVS Health Corporation (CVS) is scheduled to report its second-quarter 2016 results before the opening bell on Aug 2.
ZBH: 129.40 (+1.05), CVS: 93.84 (+0.47), BMY: 56.35 (-0.41), HOLX: 38.51 (+0.05)
NuVasive (NUVA) Beats on Q2 Earnings, Raises FY16 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:27PM CDT
NuVasive, Inc. (NUVA) reported second-quarter 2016 adjusted earnings per share (EPS) of 40 cents, reflecting a 29% rise from the year-ago quarter.
BSX: 24.26 (-0.07), ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), NUVA: 66.74 (+0.68)
Zimmer Biomet Announces Enhancements to Joint Reconstruction Portfolio for the Treatment of Patients with Significant Bone Loss
PR Newswire - Thu Jun 16, 3:30PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the global commercial launch of new enhancements to its OSS(TM) Orthopedic Salvage System, a comprehensive set of joint reconstruction prostheses designed to treat patients suffering from bone loss due to tumor resection, ligamentous deficiencies, orthopaedic trauma or patients who have undergone multiple knee and hip revision arthroplasties.
ZBH: 129.40 (+1.05)
LDR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of LDR Holding Corporation (LDRH) Over the Proposed Sale of the Company to Zimmer Biomet Holdings, Inc.
PR Newswire - Wed Jun 15, 10:18AM CDT
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of LDR Holding Corporation ("LDR" or the "Company" (NASDAQ:LDRH) for potential breaches of fiduciary duties in connection with the sale of the Company to Zimmer Biomet Holdings, Inc. for approximately $1.0 billion.
ZBH: 129.40 (+1.05), LDRH: 36.98 (-0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into the Fairness of the Sale of LDR Holding Corporation to Zimmer Biomet Holdings, Inc. - LDRH
PR Newswire - Thu Jun 09, 10:20AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
ZBH: 129.40 (+1.05), LDRH: 36.98 (-0.02)
LDR (LDRH) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of LDR Holding Corporation; Is $37.00 a Fair Price?
PR Newswire - Wed Jun 08, 7:14PM CDT
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of LDR Holding Corporation (NASDAQ: LDRH) breached their fiduciary duties in connection with the proposed sale of the Company to Zimmer Biomet Holdings, Inc. (NYSE: ZBH).
ZBH: 129.40 (+1.05), LDRH: 36.98 (-0.02)
Zimmer Biomet's Spine Business to Get a Boost with LDR Buy
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:00AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) has entered into a definitive agreement to acquire LDR Holding Corp. (LDRH) for a total deal value of $1 billion.
BSX: 24.26 (-0.07), ICUI: 126.98 (+1.77), ZBH: 129.40 (+1.05), LDRH: 36.98 (-0.02)
Zimmer Biomet's LDR Buyout On Track, Dental Still a Pain
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:45AM CDT
On Sep 2, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Zimmer Biomet Holdings to Present at INVESTIndiana Equity Conference
PR Newswire - Thu Sep 01, 3:30PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced that it will be participating in the INVESTIndiana Equity Conference at the Indianapolis Marriott Downtown on Thursday, September 15, 2016 at 1:10 p.m. Eastern Time.
ZBH: 129.40 (+1.05)
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2016
PR Newswire - Tue Aug 23, 6:30AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2016.
ZBH: 129.40 (+1.05)
Zimmer Biomet Holdings to Present at Morgan Stanley 2016 Global Healthcare Conference
PR Newswire - Thu Aug 18, 4:00PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced that it will be participating in the Morgan Stanley 2016 Global Healthcare Conference at the Grand Hyatt hotel in New York. Zimmer Biomet will present on Monday, September 12, 2016 at 9:20 a.m. Eastern Time.
ZMH: 113.56 (+0.29), ZBH: 129.40 (+1.05), MS: 31.89 (-0.02)
Technical Roundup on Medical Appliances & Equipment Stocks -- Zimmer Biomet, Stryker, ABIOMED, and Spectranetics
PR Newswire - Thu Aug 18, 7:31AM CDT
Stock-Callers.com is currently focused on the Medical Appliances and Equipment segment, which includes companies that manufacture medical supplies such as surgical and medical instruments, dental equipment, and surgical appliances. According to IBISWorld, global revenue of this industry is about $350 billion. Let us take a look at today's lineup: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Stryker Corp. (NYSE: SYK), ABIOMED Inc. (NASDAQ: ABMD), and The Spectranetics Corp. (NASDAQ: SPNC). Sign up today and download for free the research reports for the stocks covered today at:
SPNC: 24.86 (+0.17), ABMD: 117.43 (-0.20), ZBH: 129.40 (+1.05), SYK: 115.60 (+0.37)
Zimmer Biomet Acquires CD Diagnostics, Targets PJI Market
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:27AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) announced the buyout of CD Diagnostics, an immunoassays and biomarker testing developer.
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Zimmer Biomet to Present at 11th Annual Wells Fargo Securities Healthcare Conference
PR Newswire - Tue Aug 16, 4:00PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that it will be participating in the 11th Annual Wells Fargo Securities Healthcare Conference at the Westin Boston Waterfront hotel in Boston, Massachusetts. Zimmer Biomet will present on Wednesday, September 7, 2016 at 9:55 a.m. Eastern Time.
ZBH: 129.40 (+1.05), WFC: 50.55 (+0.12)
Zimmer Biomet Strengthens Musculoskeletal Diagnostic Offering with Acquisition of CD Diagnostics
PR Newswire - Mon Aug 15, 7:03AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the acquisition of CD Diagnostics, a fully-integrated, Delaware-based diagnostics company focused on developing immunoassays and biomarker testing to inform treatment decisions that improve patient outcomes. The financial terms of the transaction were not disclosed.
ZBH: 129.40 (+1.05)
Zimmer Biomet Holdings Announces Pricing of Secondary Offering of Common Stock
PR Newswire - Wed Aug 10, 7:19AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced the pricing of the previously announced underwritten secondary offering of 7,440,675 shares of its common stock by certain of its stockholders, consisting of affiliates of KKR and TPG. The shares are being sold to the public at an initial price of $129.75 per share. The selling stockholders will receive all of the proceeds of the offering. Neither Zimmer Biomet nor any of its directors, officers or other stockholders is selling any shares of common stock in the offering. The closing of the offering is expected to occur on August 12, 2016, subject to the satisfaction of customary closing conditions.
ZBH: 129.40 (+1.05)
Zimmer Biomet Holdings Announces Launch of Secondary Offering of Common Stock
PR Newswire - Tue Aug 09, 3:08PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that certain of its stockholders, consisting of affiliates of KKR and TPG, intend to offer for sale in an underwritten secondary offering 7,440,675 shares of the common stock of Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"
. The selling stockholders will receive all of the proceeds of the offering. Neither Zimmer Biomet nor any of its directors, officers or other stockholders is offering shares of common stock in the offering. ZBH: 129.40 (+1.05)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Raises FY16 Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 1:57PM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported second-quarter 2016 adjusted earnings per share (EPS) of $2.02, up 27.8% year over year.
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), BAX: 46.28 (+0.10), VASC: 48.99 (+0.53)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Revenue Estimates
Aparajita Dutta - Zacks Investment Research - Thu Jul 28, 7:56AM CDT
Zimmer Biomet's (ZBH) adjusted earnings per share of $2.02 beat this estimate by 3.1%.
ZBH: 129.40 (+1.05)
Zimmer Biomet Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Jul 28, 6:30AM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2016. The Company reported second quarter net sales of $1.93 billion, an increase of 65.6% and an increase of 4.5% on an adjusted pro forma, constant currency basis, compared to the second quarter of 2015. Diluted net loss per share for the quarter was $(0.16), compared to a net loss per share of $(1.00) for the prior year period, and adjusted diluted earnings per share for the quarter were $2.02, an increase of 27.8% adjusted over the prior year period.
ZBH: 129.40 (+1.05)
CVS Health (CVS) Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:43PM CDT
CVS Health Corporation (CVS) is scheduled to report its second-quarter 2016 results before the opening bell on Aug 2.
ZBH: 129.40 (+1.05), CVS: 93.84 (+0.47), BMY: 56.35 (-0.41), HOLX: 38.51 (+0.05)
NuVasive (NUVA) Beats on Q2 Earnings, Raises FY16 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:27PM CDT
NuVasive, Inc. (NUVA) reported second-quarter 2016 adjusted earnings per share (EPS) of 40 cents, reflecting a 29% rise from the year-ago quarter.
BSX: 24.26 (-0.07), ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), NUVA: 66.74 (+0.68)
Zimmer Biomet Announces Enhancements to Joint Reconstruction Portfolio for the Treatment of Patients with Significant Bone Loss
PR Newswire - Thu Jun 16, 3:30PM CDT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the global commercial launch of new enhancements to its OSS(TM) Orthopedic Salvage System, a comprehensive set of joint reconstruction prostheses designed to treat patients suffering from bone loss due to tumor resection, ligamentous deficiencies, orthopaedic trauma or patients who have undergone multiple knee and hip revision arthroplasties.
ZBH: 129.40 (+1.05)
LDR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of LDR Holding Corporation (LDRH) Over the Proposed Sale of the Company to Zimmer Biomet Holdings, Inc.
PR Newswire - Wed Jun 15, 10:18AM CDT
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of LDR Holding Corporation ("LDR" or the "Company"
(NASDAQ:LDRH) for potential breaches of fiduciary duties in connection with the sale of the Company to Zimmer Biomet Holdings, Inc. for approximately $1.0 billion. ZBH: 129.40 (+1.05), LDRH: 36.98 (-0.02)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into the Fairness of the Sale of LDR Holding Corporation to Zimmer Biomet Holdings, Inc. - LDRH
PR Newswire - Thu Jun 09, 10:20AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
ZBH: 129.40 (+1.05), LDRH: 36.98 (-0.02)
LDR (LDRH) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of LDR Holding Corporation; Is $37.00 a Fair Price?
PR Newswire - Wed Jun 08, 7:14PM CDT
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of LDR Holding Corporation (NASDAQ: LDRH) breached their fiduciary duties in connection with the proposed sale of the Company to Zimmer Biomet Holdings, Inc. (NYSE: ZBH).
ZBH: 129.40 (+1.05), LDRH: 36.98 (-0.02)
Zimmer Biomet's Spine Business to Get a Boost with LDR Buy
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:00AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) has entered into a definitive agreement to acquire LDR Holding Corp. (LDRH) for a total deal value of $1 billion.
BSX: 24.26 (-0.07), ICUI: 126.98 (+1.77), ZBH: 129.40 (+1.05), LDRH: 36.98 (-0.02)
(0)
(0)Scroll down for more posts ▼